10-Q
Quarterly Report
ALTO INGREDIENTS, INC.
ALTO
NASDAQ
CIK: 778164
File #: 000-21467
Balance Sheet
51 line items · 2 periods
XBRL
| Item | Jun 30, 2026 | Dec 31, 2025 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 23,962,000 | 23,415,000 |
Restricted cash | 0 | 2,258,000 |
Cash collateral balance | — | 2,258,000 |
Accounts receivable (net of allowance for credit losses of $38 and $76, respectively) | 67,889,000 | 55,069,000 |
Inventories | 51,609,000 | 61,676,000 |
Transferable tax credits, net | 8,265,000 | 7,500,000 |
Level 3 | 8,265,000 | 7,500,000 |
Derivative instruments | 4,173,000 | 525,000 |
Level 1 | 4,173,000 | 525,000 |
Commodity contracts | 4,173,000 | 525,000 |
Other current assets | 4,926,000 | 5,474,000 |
Total current assets | 160,824,000 | 155,917,000 |
Property and equipment, net | 197,479,000 | 198,501,000 |
Other Assets: | ||
Right of use operating lease assets, net | 21,492,000 | 16,931,000 |
Intangible assets, net | 7,264,000 | 7,574,000 |
Other assets | 10,011,000 | 9,863,000 |
Total other assets | 38,767,000 | 34,368,000 |
Total Assets | 397,070,000 | 388,786,000 |
Corporate and other | 26,387,000 | 32,797,000 |
Western production | 45,593,000 | 43,131,000 |
Marketing and distribution | 109,125,000 | 103,911,000 |
Pekin Campus Production | 215,965,000 | 208,947,000 |
Current Liabilities: | ||
Accounts payable | 24,219,000 | 14,509,000 |
Accrued liabilities | 16,424,000 | 16,691,000 |
Current portion – long-term debt | — | 16,600,000 |
Current portion – operating leases | 4,916,000 | 4,958,000 |
Derivative instruments | 277,000 | 1,067,000 |
Level 1 | 277,000 | 1,067,000 |
Commodity contracts | 277,000 | 1,067,000 |
Other current liabilities | 4,561,000 | 5,246,000 |
Total current liabilities | 50,397,000 | 59,071,000 |
Long-term debt, net | 60,469,000 | 63,027,000 |
Operating leases, net of current portion | 17,553,000 | 13,012,000 |
Other liabilities | 8,774,000 | 8,435,000 |
Total Liabilities | 137,193,000 | 143,545,000 |
Stockholders’ Equity: | ||
Preferred stock, $0.001 par value; 10,000 shares authorized; Series A: 1,684 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025; Series B: 1,581 shares authorized; 927 shares issued and outstanding as of June 30, 2026 and December 31, 2025; liquidation preference of $18,075 as of June 30, 2026 | 1,000 | 1,000 |
Common stock, value | 78,000 | 77,000 |
Additional paid-in capital | 1,051,085,000 | 1,051,795,000 |
Accumulated other comprehensive income | 5,461,000 | 5,461,000 |
Accumulated deficit | (796,748,000) | (812,093,000) |
Total Stockholders’ Equity | 259,877,000 | 245,241,000 |
Accum. Other Comprehensive Income | 5,461,000 | 5,461,000 |
Accumulated Deficit | (796,748,000) | (812,093,000) |
Additional Paid-In Capital | 1,051,085,000 | 1,051,795,000 |
Common Stock | 78,000 | 77,000 |
Preferred Stock | 1,000 | 1,000 |
Total Liabilities and Stockholders’ Equity | 397,070,000 | 388,786,000 |